Active — Not RecruitingPhase 4

Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome

Denmark, Finland2,201 participantsStarted 2018-06-29

Plain-language summary

The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary syndrome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Written informed consent
✓. Age ≥18 years
✓. Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery

Exclusion criteria

✕. Previously enrolled in this study (i.e. patient now at repeat encounter)
✕. Concomitant surgical procedure other than CABG
✕. Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)
✕. Discharge from the operating hospital to an ICU at another hospital
✕. Pregnancy or lactation
✕. Known intolerance or contraindication to ticagrelor or ASA
✕. Any disorder that may interfere with drug absorption
✕. Any condition other than coronary artery disease with a life expectancy \<12 months

What they're measuring

Time to major adverse cardiovascular events (MACE)

Timeframe: within12 months

Trial details

NCT IDNCT03560310

SponsorVastra Gotaland Region

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-03-13

View on ClinicalTrials.gov More Acute Coronary Syndrome trials